PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07K 14/00

A2

(11) International Publication Number: WO 99/02552

(43) International Publication Date: 21 January 1999 (21.01.99)

(21) International Application Number: PCT/IL98/00321

(22) International Filing Date: 9 July 1998 (09.07.98)

(30) Priority Data:

121284	10 July 1997 (10.07.97)	IL
122818	30 December 1997 (30.12.97)	IL

(71) Applicant *(for all designated States except US)*: YEDA RESEARCH AND DEVELOPMENT CO. LTD. [IL/IL]; Weizmann Institute of Science, P.O. Box 95, 76100 Rehovot (IL).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: REVEL, Michel [IL/IL]; Weizmann Institute of Science, Beit Brazil 5, 76100 Rehovot (IL). CHEBATH, Judith [IL/IL]; Rehov Miller 13, 76284 Rehovot (IL). LAPIDOT, Tsvee [IL/IL]; Rehov Boxer 6, 74046 Ness-Ziona (IL). KOLLET, Orit [IL/IL]; Rehov Ramat Chen 14, 52232 Ramat Gan (IL).

(74) Agent: EINAV, Henry; Inter-Lab Ltd., Science-based Industrial Park, Kiryat Weizmann, 76110 Ness-Ziona (IL).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: CHIMERIC INTERLEUKIN-6 SOLUBLE RECEPTOR/LIGAND PROTEIN, ANALOGS THEREOF AND USES THEREOF

(57) Abstract

Chimeric proteins constructed from the fusion of the naturally occurring form of the soluble IL-6 receptor and IL-6 which are useful for treatment of cancer and liver disorders, enhancement of bone marrow transplantation, and treatment of other IL-6 related conditions are provided.